|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Corvus Pharmaceuticals, Inc.
| | | Phone: | (650) 900-4520 | Year Established: | 2014 | Ticker: | CRVS | Exchange: | NASDAQ | Main Contact: | Jason V. Coloma, Ph.D., Senior VP & CBO | | Other Contacts: | Leiv Lea, CFO Ian McCaffery, Ph.D., VP, Translational Sciences Ginna G. Laport, M.D., VP, Clinical Development William Ben Jones, Ph.D., VP, Pharmaceutical Development Erik Verner, Ph.D., VP, Chemistry Research Joseph J Buggy, Ph.D., Co-Founder & Executive VP, Discovery Research Richard A Miller, M.D., President, CEO & Co-Founder
| | Company Description | Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T cells. A Phase 1B clinical trial evaluating its oral small molecule checkpoint inhibitor is scheduled to begin in the first quarter of 2016. | |
|
|
|
|
|